<DOC>
	<DOCNO>NCT00008840</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness 2 drug ( AmBisome versus voriconazole ) treat fungal infection . Immunocompromised patient , especially persistent fever neutropenia , high risk develop deeply invasive , life-threatening fungal infection Candida , Aspergillus , opportunistic fungal pathogen . The risk fungal infection increase direct proportion severity neutropenia duration fever . Antifungal therapy , therefore , important step amelioration fungal disease .</brief_summary>
	<brief_title>A Randomized , Open Label , Comparative , Multicenter Trial Voriconazole Vs. AmBisome Empirical Antifungal Therapy Immunocompromised Patients With Persistent Fever Neutropenia</brief_title>
	<detailed_description>Patients first split group receive either voriconazole AmBisome . Both drug give vein ( IV ) least 3 day . At conclusion 3 day , voriconazole patient switch oral voriconazole . The AmBisome patient continue IV AmBisome . Both group continue treatment blood count increase fever subsides .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<criteria>You may eligible study : Are least 12 year age . Are hospitalize low white blood cell count . Have receive least 96 hour IV antibiotic . Have oral temperature ( equivalent ) 38.0 C ( 100.4 F ) great within 24 hour study start . Are pregnant breastfeeding . Agree use barrier method contraception ( e.g. , condom ) study You eligible study : Have serious fungal infection . Have history allergic reaction antifungal agent . Are take certain medication may interfere study drug . Are participate clinical trial investigational drug . Have previously participate trial . Have condition could affect safety , make evaluation response difficult , make unlikely complete course therapy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2005</verification_date>
</DOC>